We recommend using Google Chrome or Windows Edge for the best experience of the TB Drug Access Atlas. Otherwise, please update your browser to the most current version to optimize this site’s features.
Internationally quality-assured (IQA) second-line drugs (SLDs) are essential to treat and cure drug resistant forms of tuberculosis, which infects half a million people annually and is responsible for close to 250,000 deaths per year. However, these drugs are often the least accessible to the populations that need them most.
This mapping tool uses data regarding ongoing and planned work to address IQA SLD supply and demand as reported by stakeholders from the mapping research project, alongside the burden of multidrug-resistant tuberculosis (MDR-TB) according to World Health Organization reports. By highlighting the areas of greatest MDR-TB burden and the areas of activity, this tool is meant to inform decision-making and encourage the sharing of experiences and resources among initiates operating in the same geographical and market areas to improve access to MDR-TB pharmaceuticals. Moreover, as this tool continues to grow in support and collaboration with stakeholders in the IQA SLD landscape, it will be updated regularly to reflect change and growth in the MDR-TB landscape.